The latest thoracic oncology news
Five-year Survival Rate For Nivolumab-treated Advanced Lung Cancer Patients Much Higher Than Historical Rate
Treatment with the immune checkpoint inhibitor nivolumab (Opdivo) yielded durable responses in some patients with…